WILKES UNIVERSITY | GRADUATE NURSING AND ADVANCED PRACTICE EDUCATION
NSG552 / NSG 552 EXAM 2 (LATEST )
PSYCHOPHARMACOLOGY
GRADE A QUESTIONS AND VERIFIED ANSWERS | 100% CORRECT - WILKES
Comprehensive Examination | 100 Questions | Seven Sections | Multiple Choice (A-D), One Best Answer
Cognitive Levels: 20% Recall, 50% Application, 30% Analysis | Aligned with the Wilkes University NSG 552 Course
Syllabus, AACN Essentials of Master's Education, and Advanced Psychopharmacology Competencies (2026/2027 Edition)
Instructions: Select the single best answer for each item. The correct answer and an evidence-based rationale grounded in NSG
552 psychopharmacology principles follow each item to support self-assessment and remediation.
Section 1: Principles of Psychopharmacology
Questions 1 through 15 | Multiple Choice (A-D), One Best Answer
Q1: A psychiatric-mental health nurse practitioner (PMHNP) initiates sertraline 50 mg daily for a
34-year-old with major depressive disorder. On day 4 the patient calls, reports no improvement, and asks
whether the dose should be increased. Which pharmacokinetic principle best guides the response?
A. Approximately 4 to 5 half-lives are needed to reach steady-state plasma concentrations, and clinical
response lags steady state, so full effect cannot be judged for 1 to 3 more weeks. *[CORRECT]*
B. Sertraline reaches steady state within 24 to 48 hours, so a dose increase is appropriate immediately.
C. Failure to respond by day 4 predicts treatment resistance and warrants an immediate switch to an
SNRI.
D. Half-life governs only the rate of elimination and has no relevance to the timing of therapeutic
response.
Correct Answer: A
Rationale: At steady state the rate of drug accumulation equals the rate of elimination; with sertraline's
roughly 26-hour half-life, 4 to 5 half-lives are required for steady plasma levels, and synaptic
neuroadaptation delays observable benefit an additional 2 or more weeks, consistent with the NSG 552
pharmacokinetics unit. Raising the dose at day 4 risks stacking side effects before efficacy is known.
Switching this early mislabels normal latency as treatment resistance, and half-life determines both
accumulation and washout, directly shaping titration and discontinuation planning as emphasized across
AACN Essentials Domain 1 (Knowledge for Nursing Practice).
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 1
,NSG552 / NSG 552 EXAM 2 (LATEST ): PSYCHOPHARMACOLOGY
Q2: A nurse practitioner student asks why a highly lipophilic antipsychotic enters brain tissue much
more readily than a hydrophilic one. Which explanation is most accurate?
A. The blood-brain barrier actively transports every psychotropic medication into the central nervous
system regardless of lipid solubility.
B. Hydrophilic drugs bind albumin more extensively and therefore cross into brain tissue faster.
C. The blood-brain barrier is built from endothelial tight junctions, so only small, lipophilic, unionized
molecules passively diffuse across, while polar or ionized drugs require transporters.
*[CORRECT]*
D. Lipophilic drugs are highly ionized at physiological pH and become trapped outside the central
nervous system.
Correct Answer: C
Rationale: Tight junctions between capillary endothelial cells create a lipophilic barrier that permits passive
diffusion mainly of small, lipid-soluble, unionized molecules, a core principle in the NSG 552 blood-brain
barrier content explaining CNS onset and distribution differences. Option A incorrectly implies universal
active transport, and high plasma protein binding actually limits the free fraction available to cross. Option D
inverts the chemistry, because ionized hydrophilic molecules are the ones excluded from the brain.
Q3: A patient stabilized on quetiapine 300 mg at bedtime develops pronounced sedation, dizziness, and
near-syncope two days after starting erythromycin for bronchitis. Which mechanism best explains this
presentation?
A. Erythromycin induces CYP3A4, accelerating quetiapine metabolism.
B. Quetiapine inhibits CYP3A4, increasing erythromycin concentrations.
C. The sedation reflects additive histamine receptor antagonism independent of metabolic change.
D. Erythromycin inhibits CYP3A4, decreasing quetiapine clearance and raising quetiapine plasma
concentrations. *[CORRECT]*
Correct Answer: D
Rationale: Quetiapine is extensively metabolized by CYP3A4, and strong inhibitors such as erythromycin
and ketoconazole markedly raise its levels, producing excess sedation and orthostasis; per NSG 552
interaction content, dose reduction and prescriber notification are required. Option A reverses the direction
of the effect, and Option B assigns inhibition to the wrong drug. Option C ignores the metabolic mechanism,
which best matches the temporal relationship between the antibiotic and the toxicity.
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 2
,NSG552 / NSG 552 EXAM 2 (LATEST ): PSYCHOPHARMACOLOGY
Q4: Before starting nortriptyline for neuropathic pain, pharmacogenomic testing identifies a patient as a
CYP2D6 poor metabolizer. What is the most appropriate prescribing adjustment?
A. Increase the starting dose by 50 percent because the genotype predicts subtherapeutic levels.
B. Reduce the starting dose, titrate conservatively, and use serum concentration monitoring during
titration. *[CORRECT]*
C. Proceed with standard dosing because genotype does not influence tricyclic pharmacokinetics.
D. Switch to paroxetine because it bypasses CYP2D6 metabolism entirely.
Correct Answer: B
Rationale: Poor CYP2D6 metabolizers clear tricyclic antidepressants slowly and reach toxic anticholinergic
and cardiac conduction effects at standard doses, so NSG 552 pharmacogenomic competencies call for lower
initial doses, cautious titration, and therapeutic drug monitoring targeting 50 to 150 ng/mL. Option A would
exaggerate toxicity risk. Option C ignores validated genotype guidance, and Option D is counterproductive
because paroxetine is itself a potent CYP2D6 inhibitor with its own interaction burden.
Q5: Which medication requires routine therapeutic drug monitoring with a well-established reference
range, making scheduled serum levels a standard of care?
A. Sertraline
B. Quetiapine
C. Nortriptyline *[CORRECT]*
D. Buspirone
Correct Answer: C
Rationale: Nortriptyline has a defined therapeutic window of 50 to 150 ng/mL, below which efficacy falls
and above which cardiac and anticholinergic toxicity rises, making it a classic monitoring drug in the NSG
552 therapeutic drug management unit along with lithium and anticonvulsants. Sertraline, quetiapine, and
buspirone lack validated concentration-response relationships, so routine levels add no clinical value and are
not part of AACN-aligned monitoring standards for those agents.
Q6: A student asks how aripiprazole can reduce psychosis without causing the high rates of
extrapyramidal symptoms seen with full antagonists. Which pharmacodynamic explanation is correct?
A. It is a dopamine D2 partial agonist: high intrinsic activity is capped, so it dampens firing in
hyperdopaminergic states while preserving stimulation in hypodopaminergic pathways.
*[CORRECT]*
B. It completely blocks D2 receptors in all pathways, like haloperidol, but at lower affinity.
C. It markedly increases presynaptic dopamine release throughout the brain.
D. It permanently converts dopamine receptors into inactive conformations.
Correct Answer: A
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 3
, NSG552 / NSG 552 EXAM 2 (LATEST ): PSYCHOPHARMACOLOGY
Rationale: D2 partial agonists act as functionally selective stabilizers, antagonizing excessive mesolimbic
dopaminergic activity while providing enough agonist tone in the nigrostriatal and tuberoinfundibular
pathways to limit extrapyramidal symptoms and prolactin elevation, a key NSG 552 pharmacodynamics
concept. Option B describes a full antagonist profile associated with high EPS risk. Option C describes
amphetamine-like releasing activity, and Option D describes a fabricated irreversible mechanism.
Q7: Which statement best describes the role of P-glycoprotein at the blood-brain barrier in
psychopharmacology?
A. It transports lipophilic drugs from blood into the brain to enhance CNS penetration.
B. It is an efflux transporter that pumps many psychotropics, including some SSRIs and antipsychotics,
back into the systemic circulation, limiting CNS exposure. *[CORRECT]*
C. It oxidizes drugs within endothelial cells as a primary elimination pathway.
D. It binds psychotropics irreversibly, permanently inactivating them.
Correct Answer: B
Rationale: P-glycoprotein (ABCB1) is an ATP-dependent efflux pump that restricts CNS entry of numerous
substrates, and its inhibition by drugs such as quinidine or genetic polymorphisms can change brain exposure
and response, a mechanism highlighted in the NSG 552 drug-transport content. Option A reverses the
direction of transport. Option C describes CYP-mediated metabolism rather than efflux, and Option D is
pharmacologically impossible for this transporter.
Q8: A 21-year-old with first-episode psychosis stopped risperidone after six weeks because of 7-kg
weight gain and returns with re-emerging suspiciousness. What is the best next step?
A. Restart the identical dose and explain that the weight gain is perceived rather than real.
B. Discontinue antipsychotic therapy permanently because the patient cannot tolerate it.
C. Add a second oral antipsychotic while continuing the original dose.
D. Explore concerns nonjudgmentally, switch to a metabolically favorable agent such as aripiprazole,
ziprasidone, or lurasidone, discuss a long-acting injectable option, and provide structured
psychoeducation. *[CORRECT]*
Correct Answer: D
Rationale: Adherence-focused management addresses the specific reason for discontinuation, substitutes a
lower metabolic-burden agent, and considers long-acting injectables early in first-episode illness to protect
against relapse, consistent with NSG 552 adherence content and AACN patient-centered care competencies.
Dismissing the concern (Option A) destroys the alliance, permanent discontinuation (Option B) invites
relapse and worsened prognosis, and indiscriminate polypharmacy (Option C) compounds metabolic and
movement side effects without solving the problem.
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 4
NSG552 / NSG 552 EXAM 2 (LATEST )
PSYCHOPHARMACOLOGY
GRADE A QUESTIONS AND VERIFIED ANSWERS | 100% CORRECT - WILKES
Comprehensive Examination | 100 Questions | Seven Sections | Multiple Choice (A-D), One Best Answer
Cognitive Levels: 20% Recall, 50% Application, 30% Analysis | Aligned with the Wilkes University NSG 552 Course
Syllabus, AACN Essentials of Master's Education, and Advanced Psychopharmacology Competencies (2026/2027 Edition)
Instructions: Select the single best answer for each item. The correct answer and an evidence-based rationale grounded in NSG
552 psychopharmacology principles follow each item to support self-assessment and remediation.
Section 1: Principles of Psychopharmacology
Questions 1 through 15 | Multiple Choice (A-D), One Best Answer
Q1: A psychiatric-mental health nurse practitioner (PMHNP) initiates sertraline 50 mg daily for a
34-year-old with major depressive disorder. On day 4 the patient calls, reports no improvement, and asks
whether the dose should be increased. Which pharmacokinetic principle best guides the response?
A. Approximately 4 to 5 half-lives are needed to reach steady-state plasma concentrations, and clinical
response lags steady state, so full effect cannot be judged for 1 to 3 more weeks. *[CORRECT]*
B. Sertraline reaches steady state within 24 to 48 hours, so a dose increase is appropriate immediately.
C. Failure to respond by day 4 predicts treatment resistance and warrants an immediate switch to an
SNRI.
D. Half-life governs only the rate of elimination and has no relevance to the timing of therapeutic
response.
Correct Answer: A
Rationale: At steady state the rate of drug accumulation equals the rate of elimination; with sertraline's
roughly 26-hour half-life, 4 to 5 half-lives are required for steady plasma levels, and synaptic
neuroadaptation delays observable benefit an additional 2 or more weeks, consistent with the NSG 552
pharmacokinetics unit. Raising the dose at day 4 risks stacking side effects before efficacy is known.
Switching this early mislabels normal latency as treatment resistance, and half-life determines both
accumulation and washout, directly shaping titration and discontinuation planning as emphasized across
AACN Essentials Domain 1 (Knowledge for Nursing Practice).
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 1
,NSG552 / NSG 552 EXAM 2 (LATEST ): PSYCHOPHARMACOLOGY
Q2: A nurse practitioner student asks why a highly lipophilic antipsychotic enters brain tissue much
more readily than a hydrophilic one. Which explanation is most accurate?
A. The blood-brain barrier actively transports every psychotropic medication into the central nervous
system regardless of lipid solubility.
B. Hydrophilic drugs bind albumin more extensively and therefore cross into brain tissue faster.
C. The blood-brain barrier is built from endothelial tight junctions, so only small, lipophilic, unionized
molecules passively diffuse across, while polar or ionized drugs require transporters.
*[CORRECT]*
D. Lipophilic drugs are highly ionized at physiological pH and become trapped outside the central
nervous system.
Correct Answer: C
Rationale: Tight junctions between capillary endothelial cells create a lipophilic barrier that permits passive
diffusion mainly of small, lipid-soluble, unionized molecules, a core principle in the NSG 552 blood-brain
barrier content explaining CNS onset and distribution differences. Option A incorrectly implies universal
active transport, and high plasma protein binding actually limits the free fraction available to cross. Option D
inverts the chemistry, because ionized hydrophilic molecules are the ones excluded from the brain.
Q3: A patient stabilized on quetiapine 300 mg at bedtime develops pronounced sedation, dizziness, and
near-syncope two days after starting erythromycin for bronchitis. Which mechanism best explains this
presentation?
A. Erythromycin induces CYP3A4, accelerating quetiapine metabolism.
B. Quetiapine inhibits CYP3A4, increasing erythromycin concentrations.
C. The sedation reflects additive histamine receptor antagonism independent of metabolic change.
D. Erythromycin inhibits CYP3A4, decreasing quetiapine clearance and raising quetiapine plasma
concentrations. *[CORRECT]*
Correct Answer: D
Rationale: Quetiapine is extensively metabolized by CYP3A4, and strong inhibitors such as erythromycin
and ketoconazole markedly raise its levels, producing excess sedation and orthostasis; per NSG 552
interaction content, dose reduction and prescriber notification are required. Option A reverses the direction
of the effect, and Option B assigns inhibition to the wrong drug. Option C ignores the metabolic mechanism,
which best matches the temporal relationship between the antibiotic and the toxicity.
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 2
,NSG552 / NSG 552 EXAM 2 (LATEST ): PSYCHOPHARMACOLOGY
Q4: Before starting nortriptyline for neuropathic pain, pharmacogenomic testing identifies a patient as a
CYP2D6 poor metabolizer. What is the most appropriate prescribing adjustment?
A. Increase the starting dose by 50 percent because the genotype predicts subtherapeutic levels.
B. Reduce the starting dose, titrate conservatively, and use serum concentration monitoring during
titration. *[CORRECT]*
C. Proceed with standard dosing because genotype does not influence tricyclic pharmacokinetics.
D. Switch to paroxetine because it bypasses CYP2D6 metabolism entirely.
Correct Answer: B
Rationale: Poor CYP2D6 metabolizers clear tricyclic antidepressants slowly and reach toxic anticholinergic
and cardiac conduction effects at standard doses, so NSG 552 pharmacogenomic competencies call for lower
initial doses, cautious titration, and therapeutic drug monitoring targeting 50 to 150 ng/mL. Option A would
exaggerate toxicity risk. Option C ignores validated genotype guidance, and Option D is counterproductive
because paroxetine is itself a potent CYP2D6 inhibitor with its own interaction burden.
Q5: Which medication requires routine therapeutic drug monitoring with a well-established reference
range, making scheduled serum levels a standard of care?
A. Sertraline
B. Quetiapine
C. Nortriptyline *[CORRECT]*
D. Buspirone
Correct Answer: C
Rationale: Nortriptyline has a defined therapeutic window of 50 to 150 ng/mL, below which efficacy falls
and above which cardiac and anticholinergic toxicity rises, making it a classic monitoring drug in the NSG
552 therapeutic drug management unit along with lithium and anticonvulsants. Sertraline, quetiapine, and
buspirone lack validated concentration-response relationships, so routine levels add no clinical value and are
not part of AACN-aligned monitoring standards for those agents.
Q6: A student asks how aripiprazole can reduce psychosis without causing the high rates of
extrapyramidal symptoms seen with full antagonists. Which pharmacodynamic explanation is correct?
A. It is a dopamine D2 partial agonist: high intrinsic activity is capped, so it dampens firing in
hyperdopaminergic states while preserving stimulation in hypodopaminergic pathways.
*[CORRECT]*
B. It completely blocks D2 receptors in all pathways, like haloperidol, but at lower affinity.
C. It markedly increases presynaptic dopamine release throughout the brain.
D. It permanently converts dopamine receptors into inactive conformations.
Correct Answer: A
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 3
, NSG552 / NSG 552 EXAM 2 (LATEST ): PSYCHOPHARMACOLOGY
Rationale: D2 partial agonists act as functionally selective stabilizers, antagonizing excessive mesolimbic
dopaminergic activity while providing enough agonist tone in the nigrostriatal and tuberoinfundibular
pathways to limit extrapyramidal symptoms and prolactin elevation, a key NSG 552 pharmacodynamics
concept. Option B describes a full antagonist profile associated with high EPS risk. Option C describes
amphetamine-like releasing activity, and Option D describes a fabricated irreversible mechanism.
Q7: Which statement best describes the role of P-glycoprotein at the blood-brain barrier in
psychopharmacology?
A. It transports lipophilic drugs from blood into the brain to enhance CNS penetration.
B. It is an efflux transporter that pumps many psychotropics, including some SSRIs and antipsychotics,
back into the systemic circulation, limiting CNS exposure. *[CORRECT]*
C. It oxidizes drugs within endothelial cells as a primary elimination pathway.
D. It binds psychotropics irreversibly, permanently inactivating them.
Correct Answer: B
Rationale: P-glycoprotein (ABCB1) is an ATP-dependent efflux pump that restricts CNS entry of numerous
substrates, and its inhibition by drugs such as quinidine or genetic polymorphisms can change brain exposure
and response, a mechanism highlighted in the NSG 552 drug-transport content. Option A reverses the
direction of transport. Option C describes CYP-mediated metabolism rather than efflux, and Option D is
pharmacologically impossible for this transporter.
Q8: A 21-year-old with first-episode psychosis stopped risperidone after six weeks because of 7-kg
weight gain and returns with re-emerging suspiciousness. What is the best next step?
A. Restart the identical dose and explain that the weight gain is perceived rather than real.
B. Discontinue antipsychotic therapy permanently because the patient cannot tolerate it.
C. Add a second oral antipsychotic while continuing the original dose.
D. Explore concerns nonjudgmentally, switch to a metabolically favorable agent such as aripiprazole,
ziprasidone, or lurasidone, discuss a long-acting injectable option, and provide structured
psychoeducation. *[CORRECT]*
Correct Answer: D
Rationale: Adherence-focused management addresses the specific reason for discontinuation, substitutes a
lower metabolic-burden agent, and considers long-acting injectables early in first-episode illness to protect
against relapse, consistent with NSG 552 adherence content and AACN patient-centered care competencies.
Dismissing the concern (Option A) destroys the alliance, permanent discontinuation (Option B) invites
relapse and worsened prognosis, and indiscriminate polypharmacy (Option C) compounds metabolic and
movement side effects without solving the problem.
NSG 552 Exam 2 | Psychopharmacology | Wilkes University 4
